REG - SkinBioTherapeutics - Board and Leadership Changes

SkinbiotherapeuticsAnnouncement

24/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX9270Fa&default-theme=true

RNS Number : 9270F  SkinBioTherapeutics PLC  24 April 2025

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Board and Leadership Changes

 

·    Appointment of Simon Hewitson as Chief Operating Officer and proposed
appointment to the SkinBioTherapeutics Board as a Director

·    Emily Bertram to be appointed as Group Finance Director, to take over
all Group financial operations

·    Current CFO, Manprit Randhawa is leaving to pursue other business
interests

24 April 2025 - SkinBioTherapeutics plc (AIM: SBTX, the Group), a life science
company focused on skin health, announces proposed changes to the Board and
leadership team to strengthen the day-to-day operational and financial
functions of the Group.

Simon Hewitson has been appointed as Chief Operating Officer to the Group and
he will also join the Board. This appointment has been agreed by the Board,
subject to completion of customary due diligence for the purposes of the AIM
Rules. In addition, Emily Bertram has been appointed as the Group's Finance
Director in a non-board capacity and will assume responsibility for financial
control and reporting, succeeding Manprit Randhawa, who is stepping down as
Chief Financial Officer to pursue other business interests.

Simon Hewitson, Chief Operating Officer

Simon Hewitson is an experienced Chartered Accountant with a strong background
in corporate finance as well as financial and commercial skills.

For the past 25+ years, Simon has worked for a number of different companies
in CEO, CFO and Director roles, having managed specific transactions for them,
including management buy outs (MBO), acquisitions, disposals or integration
into other companies. Most recently, he was the CEO and then consultant to the
iced drink company, Polar Krush Group, a corporate financier within the
Williams Ali Corporate Finance firm and Financial Director at Mill North East
where he advised on its MBO from Inchcape plc and its subsequent sale to
Stoneacre Group.  Before then, he was a Director at BTG Corporate Finance
focusing on transactions with enterprise values up to £100m and prior to
that, he was a corporate financier at the financial services firm, UNW LLP. He
also worked for Five Arrows Commercial Finance providing Asset Based Lending
solutions to support growing and acquisitive companies.

He is a qualified Chartered Accountant and he has a BA (Hons) in Business
Studies from Northumbria University.

Emily Bertram, Group Finance Director

Emily is an experienced certified Chartered Accountant (ACCA) who has led and
worked within finance teams in a variety of industries, from business advisory
groups to medical technology and pharma companies, to banking.

Most recently, Emily has been the Group Head of Financial Planning and
Analysis at Azets, the international business advisory group. Previously, she
spent a brief time at SkinBioTherapeutics where she was responsible for the
whole finance function under Manprit Randhawa. Prior to this, she held senior
finance positions at THF Holdings, Leica Biosystems, Quantum Pharma,
Northumbria University (Faculty of Health & Life Sciences), Alta Link and
Northern Rock.

She has a 1(st) class BA (Hons) in Accounting from Northumbria University.

Martin Hunt, Chair of SkinBioTherapeutics said: "The Group's needs have
changed substantially over the past 18 months with an active M&A strategy
and the successful launch of the Croda Zenakine™ (SkinBiotix®) active
ingredient. As a result of which, we identified a need to strengthen the Board
and leadership team, especially the support required by Stuart to drive the
Group's growth further. We have been very fortunate to have found two
excellent new team members in Simon and Emily, and on behalf of the Board, we
thank Manprit for his work as CFO and wish him well in the future.

"Simon has extensive corporate finance experience in M&A and the
operational management following the deals to ensure they succeeded. He will
provide Stuart with valuable support, especially in the day-to-day operations
of the expanded Group, and will bring additional financial and investor
relations experience to the Board.

"We are also delighted to have Emily returning to us as our Finance Director.
Emily has a good knowledge of SkinBioTherapeutics' financial systems having
worked in the finance team previously, and she is a very safe and experienced
pair of hands having worked across multiple industries. We welcome her back in
her new elevated role as Group FD."

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Martin Hunt, Chair

 Stuart J. Ashman, CEO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements to modulate the immune system by harnessing the gut-skin
axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and
the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to
address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGZGZDVFNGKZM